2024-04-23 08:54Financial Performance - The company's revenue for Q1 2024 was RMB 3,242.81 million, a decrease of 4.99% compared to RMB 3,413.06 million in the same period last year[4] - Net profit attributable to shareholders was RMB 607.82 million, an increase of 4.45% from RMB 581.91 million year-on-year[4] - Basic and diluted earnings per share were both RMB 0.65, reflecting a growth of 4.84% from RMB 0.62 in the same quarter last year[4] - The total comprehensive income for the period was RMB 693,127,170.79, compared to RMB 547,848,808.47 in the previous year, indicating a growth of 26.5%[25] - The investment income decreased by 58.41% to RMB 15.72 million, down from RMB 37.80 million in the previous year, primarily due to last year's dividend income[12] Cash Flow - The net cash flow from operating activities surged by 208.30%, reaching RMB 924.25 million compared to RMB 299.78 million in the previous year[4] - The net cash flow from operating activities increased significantly to ¥924,248,920.31, compared to ¥299,784,593.85 in the previous period, marking a growth of approximately 208%[27] - Cash inflow from operating activities totaled ¥3,508,763,815.99, up from ¥3,446,124,787.42, indicating a slight increase of about 1.8%[27] - Cash outflow from operating activities decreased to ¥2,584,514,895.68 from ¥3,146,340,193.57, representing a reduction of approximately 17.9%[27] - The net cash flow from investing activities was negative at -¥457,336,601.18, worsening from -¥64,826,182.09 in the previous period[27] - The net cash flow from financing activities showed a net outflow of RMB 654.61 million, a decrease of 306.71% compared to a net inflow of RMB 316.69 million in the previous year, due to reduced new borrowings and increased loan repayments[14] Assets and Liabilities - Total assets at the end of the reporting period were RMB 25,189.70 million, a slight increase of 0.58% from RMB 25,044.83 million at the end of the previous year[5] - The total liabilities decreased to RMB 9,750,195,000.46 from RMB 10,278,124,131.71, reflecting a reduction of approximately 5.12%[24] - The total current assets as of March 31, 2024, amounted to RMB 17,178,219,962.61, a slight decrease from RMB 17,266,174,718.28 at the beginning of the year[23] - The total non-current assets increased to RMB 8,011,475,794.50 from RMB 7,778,652,409.47 at the beginning of the year[23] Shareholder Information - Shareholders' equity attributable to the parent company increased by 4.01% to RMB 14,606.16 million from RMB 14,042.50 million[5] - The total number of ordinary shareholders at the end of the reporting period was 43,751, with the top ten shareholders holding 33.41% of the shares[15] - As of March 31, 2024, the company repurchased a total of 2,152,600 A-shares, accounting for 0.23% of the total share capital, with a total expenditure of RMB 73,436,534.00[18] - The company also repurchased 2,476,300 H-shares, representing 0.27% of the total share capital, with a total expenditure of HKD 60,363,260.00[19] Operational Highlights - The company plans to continue expanding its market presence and investing in new product development to drive future growth[3] - The company reported a significant increase in minority shareholders' profit, which rose by 238.80% to RMB 108.26 million from RMB 31.95 million in the previous year[12] - The revenue from gastrointestinal products decreased by 25.68% to RMB 588.96 million, while revenue from hormone products increased by 39.89% to RMB 806.93 million[12] - The company experienced a 60.26% increase in revenue from diagnostic reagents and equipment, reaching RMB 235.58 million compared to the previous year[12] Expenses - Research and development expenses for the quarter were RMB 238,173,559.46, down 23.5% from RMB 311,408,248.52 in the previous year[25] - The company reported a decrease in sales expenses to RMB 876,113,247.33 from RMB 964,906,980.93, a decline of 9.2%[25] - The company reported a 522.72% increase in financial expenses, primarily due to increased interest income from deposits[12] Stock Options - The company has a total of 1,001 incentive participants eligible to exercise 7,045,000 stock options at an exercise price of RMB 31.31 per A-share[20] - As of March 31, 2024, 270.66 thousand stock options have been exercised by the incentive participants[21] Buyback Information - The highest purchase price for A-shares during the buyback was RMB 35.15 per share, while the lowest was RMB 32.95 per share[18] - The highest purchase price for H-shares during the buyback was HKD 25.15 per share, with a lowest price of HKD 23.05 per share[19] Cash and Cash Equivalents - The company's cash and cash equivalents stood at RMB 11,143,148,609.60, a decrease from RMB 11,325,723,855.76 at the beginning of the year[23] - The ending cash and cash equivalents balance was ¥10,787,974,836.57, slightly down from ¥10,600,468,696.85[27] Audit Information - The company did not undergo an audit for the first quarter report[28]